New shot tested for Tough-to-Treat Crohn's disease
NCT ID NCT05910528
Summary
This study is testing a new injectable medication called Afimkibart for adults with moderate to severe Crohn's disease who haven't gotten enough relief from standard treatments. Researchers want to see if the treatment is safe and if it can reduce gut inflammation and symptoms like diarrhea and abdominal pain. The study is in Phase 2, meaning it's still being tested to find the right dose and see how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta
Roeselare, 8800, Belgium
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
CHRU de Nancy Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU de Nantes
Nantes, 44093, France
-
Clinical Research Institute of Michigan
Chesterfield, Michigan, 48047, United States
-
Digestive Health Specialists
Dothan, Alabama, 36305, United States
-
I.H.S Health Northwell Health
Kissimmee, Florida, 34741, United States
-
Institut des MICI, Clinique Ambroise Paré
Neuilly-sur-Seine, 92200, France
-
Medical Research Center of Connecticut, LLC
Hamden, Connecticut, 06518, United States
-
Twoja Przychodnia-Szczecinskie Centrum Medyczne
Szczecin, 71-434, Poland
-
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 00-728, Poland
Conditions
Explore the condition pages connected to this study.